Development and validation of a method to determine the unbound paclitaxel fraction in human plasma

H.J.G.D. van den Bongard(Slotervaartziekenhuis), Jos H. Beijnen(The Netherlands Cancer Institute), Ron A. A. Mathôt(Amsterdam University Medical Centers), Jan H.M. Schellens(Utrecht University), Hilde Rosing(The Netherlands Cancer Institute), Olaf van Tellingen(Dutch Cancer Society), E. Marleen Kemper(Amsterdam University Medical Centers)
Analytical Biochemistry
November 20, 2003
10.1016/j.ab.2003.07.024
Cited by 14

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884